PRESS RELEASE

MedChannels Introduces the SafetyNETTM Adverse Events Reporting System

LAS VEGAS, NV, Feb. 07, 2008 /PRNewswire-FirstCall/ -- MedChannels, a state of Ohio limited liability corporation, has launched the deployment of SafetyNET Adverse Event Reporting System (AERS). From investigative site pharmacovigilance to e-submission, SafetyNET manages the collection, coding, reporting and analysis of critical safety data.

Notes Martin James, President of MedChannels, "An escalation in the number of adverse events reported to regulators and announced to the general population in recent years has created a need for automated adverse event tracking and reporting tools in biopharmaceutical organizations of all types and sizes. Accurate, timely and complete data about adverse events are critical to preventing safety problems and helping manage public perceptions."

Regulatory requirements in the pharmacovigilance area include tight deadlines for reporting the most serious cases as well as complex ongoing requirements for reporting, tracking and analyzing all adverse events and incidents that occur. As regulators move toward requiring electronic submission of case reports, technology that manages the collection, coding, reporting and analysis of safety data has become critical.

The SafetyNET 3.1 product integrates with MedChannels' Electronic Study Submissions Module (ES2), automating the exchange of electronic case safety information with regulatory agencies, affiliates and trading partners. Report status information, like submission and recipient acknowledgement, is visible in the SafetyNET environment.
Physicians interested in participating in this unique product can get more information at SafetyNET Product Page . Alternatively, MedChannels can send hard copy sales and marketing information by emailing your request to: Mail SafetyNET brochures or calling Martin James at 614-730-1345.
MedChannels is a leading provider of life science development and commercialization services and has regional distribution hubs in Columbus, Ohio and San Antonio, Texas with headquarters in Las Vegas, NV. Its principal activities are to provide integrated product development and commercial enrichment solutions to the pharmaceutical, biotechnology and medical device industries. The Group operates in three business segments, namely Product Development, Commercialization Services and the Informatics group. The Product Development group is primarily responsible for all phases of pre-clinical and clinical research. The Commercialization Services group is primarily responsible for sales force deployment and strategic marketing services including healthcare policy research and consulting services. The Informatics group is primarily responsible for providing market research solutions and strategic analyses to support healthcare decisions.
* * * * * * * * * * * * *
Statements in this release concerning expectations for the future are forward-looking statements. A variety of known and unknown risks, uncertainties and other factors could cause actual results, performance and expectations to differ materially from anticipated results, performance or expectations. These risks, uncertainties and other factors are discussed in the company's annual report and other documents filed from time to time with the appropriate regulatory agency.

http://tbutton.prnewswire.com/prn/b1690X77317545
SOURCE: MedChannels, Inc.
Web site: http: //www.medchannels.com
CONTACT: John Davidson, Investor Relations of MedChannels, Inc., +1-614-730-1345

* * * * * * * * * * * * *